company background image
ARVN logo

Arvinas NasdaqGS:ARVN Stock Report

Last Price

US$50.60

Market Cap

US$3.4b

7D

2.5%

1Y

47.2%

Updated

21 Feb, 2024

Data

Company Financials +

ARVN Stock Overview

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.

ARVN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Arvinas, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Arvinas
Historical stock prices
Current Share PriceUS$50.60
52 Week HighUS$53.08
52 Week LowUS$13.57
Beta1.96
1 Month Change38.44%
3 Month Change136.34%
1 Year Change47.22%
3 Year Change-33.54%
5 Year Change156.98%
Change since IPO215.26%

Recent News & Updates

Recent updates

News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

Aug 13
News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price

May 05
There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price

Calculating The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)

Feb 24
Calculating The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)

Arvinas initiated Overweight at Barclays on attractive therapeutic platform

Sep 09

Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment

Aug 19

Arvinas: Still Holding, Just Not Buying More

May 23

Arvinas: One Of The Most Interesting Science-Heavy Emerging Biopharma

Feb 07

Arvinas: 2022 Is Full Of Catalysts For This Protein Degrader Pioneer

Nov 19

News Flash: Analysts Just Made A Huge Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

Aug 13
News Flash: Analysts Just Made A Huge Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

Arvinas: Tremendous Value Increase With Pfizer Mega-Deal, High Potential

Aug 01

Shareholder Returns

ARVNUS PharmaceuticalsUS Market
7D2.5%0.8%-0.5%
1Y47.2%20.2%22.3%

Price Volatility

Is ARVN's price volatile compared to industry and market?
ARVN volatility
ARVN Average Weekly Movement12.5%
Pharmaceuticals Industry Average Movement10.1%
Market Average Movement6.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

About the Company

FoundedEmployeesCEOWebsite
2013415John Houstonhttps://www.arvinas.com

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial.

Arvinas, Inc. Fundamentals Summary

How do Arvinas's earnings and revenue compare to its market cap?
ARVN fundamental statistics
Market capUS$3.44b
Earnings (TTM)-US$295.40m
Revenue (TTM)US$159.40m

21.6x

P/S Ratio

-11.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ARVN income statement (TTM)
RevenueUS$159.40m
Cost of RevenueUS$0
Gross ProfitUS$159.40m
Other ExpensesUS$454.80m
Earnings-US$295.40m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-4.34
Gross Margin100.00%
Net Profit Margin-185.32%
Debt/Equity Ratio0.2%

How did ARVN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.